Participatory notes under scrutiny as they reach peak

The demise of participatory notes and other access derivatives has long been predicted amid regulatory clampdowns and permission increasingly being given to investors to access markets directly. Funding issues have also caused headaches for swaps issuers and there are concerns Basel III charges may hurt some products. But market activity remains robust. Harry Thompson reports


Participatory notes, more commonly know as p-notes, and other access derivatives instruments, such as swaps, have come in for a fair amount of scrutiny by regulators during the past five years. These over-the-counter instruments are highly lucrative for international dealers with onshore licences in restricted markets, which issue delta one notes giving investors exposure to capital gains and dividends. Swaps are also a popular way to access onshore markets, particularly with hedge funds, where

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here